Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRONIA-CAT trial of long-term tinzaparin thromboprophylaxis in high-risk breast or prostate cancer
2018-001230-18Phase 3Terminated
- Sponsor
- Hellenic Genito-Urinary Cancer Group
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tinzaparin in venous thromboembolism (VTE) (2 arms), sponsored by Hellenic Genito-Urinary Cancer Group. Started Dec 2018; status: terminated.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2018-001230-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001230-18.